Combination therapy with recombinant human erythropoietin, interferon-alpha-2b and granulocyte-macrophage colony-stimulating factor in idiopathic myelofibrosis
| dc.contributor.author | Bourantas, K. L. | en |
| dc.contributor.author | Tsiara, S. | en |
| dc.contributor.author | Christou, L. | en |
| dc.contributor.author | Repousis, P. | en |
| dc.contributor.author | Konstantinidou, P. | en |
| dc.contributor.author | Bai, M. | en |
| dc.contributor.author | Seferiadis, K. | en |
| dc.date.accessioned | 2015-11-24T19:29:32Z | |
| dc.date.available | 2015-11-24T19:29:32Z | |
| dc.identifier.issn | 0001-5792 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/22977 | |
| dc.rights | Default Licence | - |
| dc.subject | Aged | en |
| dc.subject | Bone Marrow/pathology | en |
| dc.subject | Erythropoietin/*therapeutic use | en |
| dc.subject | Female | en |
| dc.subject | Granulocyte-Macrophage Colony-Stimulating Factor/*therapeutic use | en |
| dc.subject | Hemoglobins/metabolism | en |
| dc.subject | Humans | en |
| dc.subject | Interferon-alpha/*therapeutic use | en |
| dc.subject | Leukocyte Count | en |
| dc.subject | Male | en |
| dc.subject | Middle Aged | en |
| dc.subject | Platelet Count | en |
| dc.subject | Primary Myelofibrosis/blood/pathology/*therapy | en |
| dc.subject | Recombinant Proteins/therapeutic use | en |
| dc.subject | Spleen/pathology | en |
| dc.subject | beta 2-Microglobulin/metabolism | en |
| dc.title | Combination therapy with recombinant human erythropoietin, interferon-alpha-2b and granulocyte-macrophage colony-stimulating factor in idiopathic myelofibrosis | en |
| heal.abstract | Seven patients, 3 men and 4 women 48-72 years of age and suffering from idiopathic myelofibrosis were given a combination of recombinant human erythropoietin (r-hu-Epo), interferon-alpha-2b (IFN) and GM-CSF, in an attempt to treat their pancytopenia and marrow fibrosis. The dose of r-hu-Epo was 200 U/kg 3 times weekly, that of IFN was 3 x 10(6)/U 3 times weekly, and that of GM-CSF was 250 micrograms/m2/daily. The duration of therapy ranged from 3 to 6 months for r-hu-Epo and IFN and was 3 weeks for GM-CSF. The treatment regimen had a beneficial effect on all patients. The levels of hemoglobin increased in all patients but particularly in 5 (2 of whom had been dependent on red blood cell transfusions). Splenomegaly decreased significantly in 4 patients. Fibrosis in the bone marrow decreased in 2 patients. Three patients also had an increase in the number of white blood cells during the therapy with GM-CSF. We observed mild side effects in 6 of our patients. One patient had severe side effects from IFN and treatment was discontinued. In conclusion, the combination of r-hu-Epo, IFN and GM-CSF may improve the anemia (due to r-hu-Epo), increase the white blood cell count (due to GM-CSF) and reduce the marrow fibrosis (probably due to IFN) in patients with idiopathic myelofibrosis. | en |
| heal.access | campus | - |
| heal.fullTextAvailability | TRUE | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/8701705 | - |
| heal.identifier.secondary | http://content.karger.com/ProdukteDB/produkte.asp?doi=10.1159/000203720 | - |
| heal.journalName | Acta Haematol | en |
| heal.journalType | peer-reviewed | - |
| heal.language | en | - |
| heal.publicationDate | 1996 | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.type | journalArticle | - |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.type.en | Journal article | en |
Αρχεία
Φάκελος/Πακέτο αδειών
1 - 1 of 1
Φόρτωση...
- Ονομα:
- license.txt
- Μέγεθος:
- 1.74 KB
- Μορφότυπο:
- Item-specific license agreed upon to submission
- Περιγραφή: